SCHEMBL14744772

SCHEMBL14744772

CCOC(=O)c1ccc2c(cc(C)n2C)c1OCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.49
LMNA P02545 2/20 0.49
GAA P10253 2/20 0.49
ALDH1A1 P00352 1/20 0.49
HPGD P15428 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
TSHR P16473 2/20 0.47
MEN1 O00255 6/20 0.47
KMT2A Q03164 6/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
PKM P14618 2/20 0.46
MAPT P10636 1/20 0.46
ALOX5 P09917 1/20 0.45
HSP90AA1 P07900 1/20 0.45
MAOB P27338 1/20 0.43
NMT1 P30419 2/20 0.43
NMT2 O60551 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14744771 0.79 LMNA (0.48) KDM4ELMNAGAAALDH1A1HPGD
SCHEMBL23796493 0.74 MEN1 (0.59) LMNAALDH1A1HPGDTSHRMEN1
SCHEMBL28877532 0.74 ALDH1A1 (0.56) LMNAALDH1A1HPGDTSHRMEN1
SCHEMBL17848969 0.74 KDM4E (0.47) KDM4EGAAALDH1A1HPGDSMN1; SMN2
SCHEMBL3424497 0.74 TSHR (0.66) KDM4ELMNAGAAALDH1A1HPGD
SCHEMBL9321664 0.73 MEN1 (0.52) KDM4ELMNAALDH1A1HPGDSMN1; SMN2
SCHEMBL17961926 0.73 TSHR (0.55) KDM4EGAAALDH1A1HPGDSMN1; SMN2
SCHEMBL6797552 0.73 KDM4E (0.49) KDM4ELMNAGAAALDH1A1HPGD
SCHEMBL23796824 0.72 MEN1 (0.60) KDM4ELMNAALDH1A1TSHRMEN1
SCHEMBL8980579 0.72 TSHR (0.53) KDM4EALDH1A1HPGDSMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP KDM4E 4305/4885LMNA 2119/4885GAA 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.